Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Interest & Investment Income (2016 - 2025)

CytomX Therapeutics' Interest & Investment Income history spans 12 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 15.88% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.2 million, down 27.05%, while the annual FY2025 figure was $5.2 million, 27.05% down from the prior year.
  • Interest & Investment Income reached $1.5 million in Q4 2025 per CTMX's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.7 million in Q3 2023 to a low of $44000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $1.2 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: crashed 93.67% in 2021, then soared 3322.06% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $73000.0 in 2021, then surged by 902.74% to $732000.0 in 2022, then soared by 241.94% to $2.5 million in 2023, then plummeted by 48.94% to $1.3 million in 2024, then increased by 15.88% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Interest & Investment Income are $1.5 million (Q4 2025), $1.6 million (Q3 2025), and $1.2 million (Q2 2025).